---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-061077"
form_type: "8-K"
ticker: "FATE"
cik: "0001434316"
company_name: "FATE THERAPEUTICS INC"
filed_at: "2023-11-08T23:59:59+00:00"
generated_at: "2026-06-08T09:06:23.359414+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Fate Therapeutics Q3 2023: $350M cash, multiple IND clearances, FT522 enrollment started

## Summary
- Cash, cash equivalents & investments $349.7M as of Sept 30, 2023; runway into 2H25.
- Revenue $1.9M from ONO collaboration; GAAP operating expenses $53.2M (R&D $34.3M, G&A $18.9M).
- FT522 Phase 1 open for enrollment in B-cell lymphoma; 3-dose cohort at 300M cells per dose.
- IND cleared for FT825/ONO-8250 CAR T targeting HER2 in solid tumors; Phase 1 start-up ongoing.
- IND cleared for FT819 CAR T in systemic lupus erythematosus; Phase 1 design includes single dose with preconditioning.

## SEC filing metadata
- accession: 0000950170-23-061077
- form_type: 8-K
- ticker: FATE
- cik: 0001434316
- company_name: FATE THERAPEUTICS INC
- filed_at: 2023-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434316/000095017023061077/0000950170-23-061077-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434316/000095017023061077/fate-20231108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-061077
- JSON: https://secwatch.observer/filing/0000950170-23-061077.json
- Plain text: https://secwatch.observer/filing/0000950170-23-061077.txt

## Key facts
- Earnings Releases
  FATE THERAPEUTICS INC reported financial results for the third quarter ended September 30, 2023.
  - Period: the third quarter ended September 30, 2023
  - Result: reported results
  source text: On November 8, 2023, Fate Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1434316/000095017023061077/0000950170-23-061077-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.